Literature DB >> 9258816

No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry.

M L Møller1, O Braendstrup.   

Abstract

Immunohistochemistry for the expression of the proliferation markers proliferating cell nuclear antigen (PCNA) and Ki-67 was studied in 16 non recurring meningiomas, 11 meningiomas recurring as benign tumors, 6 recurring as atypical meningiomas and in 9 recurring as malignant meningiomas. Non recurring meningiomas were defined in this study as tumors without recurrence at least 8 years after surgery. In addition 16 benign recurrences, 14 atypical- and 12 malignant meningiomas were studied. In each group great variation of labeling indices (LI) = per cent of tumor cells labeled was observed, especially of PCNA LIs. The non recurring meningiomas displayed lower mean LI for PCNA and Ki-67 than did the recurring meningiomas of all groups but the differences were not statistically significant. The same pattern was seen when totally resected tumors were studied alone. Benign-, atypical-, and malignant meningiomas had labeling indices that were related to the grade of malignancy. Only PCNA LIs of atypical- and malignant meningiomas were statistically significantly higher than PCNA LIs of non recurring meningiomas. The study indicates that PCNA and Ki-67 are of minor value as predictors of recurrence of benign meningiomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258816     DOI: 10.1023/a:1005794700267

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  The complexities of proliferating cell nuclear antigen.

Authors:  D McCormick; P A Hall
Journal:  Histopathology       Date:  1992-12       Impact factor: 5.087

2.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  D SIMPSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

3.  AgNOR counts in recurrent and non-recurrent meningiomas.

Authors:  A Bagni; A Botticelli; A Martinelli; P Azzoni; G P Trentini
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

4.  The implications of the heterogeneous distribution of Ki-67 labelled cells in meningiomas.

Authors:  H P Siegers; P Zuber; M F Hamou; G D van Melle; N de Tribolet
Journal:  Br J Neurosurg       Date:  1989       Impact factor: 1.596

5.  Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.

Authors:  M Shibuya; T Hoshino; S Ito; M R Wacker; M D Prados; R L Davis; C B Wilson
Journal:  Neurosurgery       Date:  1992-04       Impact factor: 4.654

6.  Histological subtypes and prognostic problems in meningiomas.

Authors:  K Jellinger; F Slowik
Journal:  J Neurol       Date:  1975       Impact factor: 4.849

7.  Histopathologic features predicting recurrence of meningiomas following subtotal resection.

Authors:  S M de la Monte; J Flickinger; R M Linggood
Journal:  Am J Surg Pathol       Date:  1986-12       Impact factor: 6.394

8.  The significance of nucleolar organizer region (AgNOR) score in predicting meningioma recurrence.

Authors:  K Kunishio; T Ohmoto; T Matsuhisa; T Maeshiro; T Furuta; K Matsumoto
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

9.  Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens.

Authors:  S Khoshyomn; H Maier; T Morimura; K Kitz; H Budka
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

10.  Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites.

Authors:  R Bravo; H Macdonald-Bravo
Journal:  J Cell Biol       Date:  1987-10       Impact factor: 10.539

View more
  9 in total

1.  Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.

Authors:  Francesco Maiuri; Marialaura Del Basso De Caro; Felice Esposito; Paolo Cappabianca; Viviana Strazzullo; Guido Pettinato; Enrico de Divitiis
Journal:  J Neurooncol       Date:  2007-01-17       Impact factor: 4.130

2.  Proliferation potential of spinal meningiomas.

Authors:  Florian Roser; Makoto Nakamura; Mattia Bellinzona; Rainer Ritz; Helmut Ostertag; Marcos S Tatagiba
Journal:  Eur Spine J       Date:  2005-05-31       Impact factor: 3.134

3.  Skull base meningiomas: neurological outcome after microsurgical resection.

Authors:  Judith Scheitzach; Karl-Michael Schebesch; Alexander Brawanski; Martin A Proescholdt
Journal:  J Neurooncol       Date:  2013-11-21       Impact factor: 4.130

4.  Prognostic value of proliferation index and expression of the RNA component of human telomerase (hTR) in papillary meningiomas.

Authors:  E J Rushing; S M Colvin; A Gazdar; N Miura; C L White; C Coimbra; D K Burns
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  Absence of histological signs of tumor progression in recurrences of completely resected meningiomas.

Authors:  Davide Schiffer; Chiara Ghimenti; Valentina Fiano
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

6.  Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue.

Authors:  Wolfgang K Pfisterer; Stephen W Coons; Fahmy Aboul-Enein; William P Hendricks; Adrienne C Scheck; Mark C Preul
Journal:  J Neurooncol       Date:  2007-11-30       Impact factor: 4.130

7.  Degree of Resection and Ki-67 Labeling Index for Recurring Meningiomas.

Authors:  Richard Menger; David E Connor; Alvin Y Chan; Gary Jain; Anil Nanda
Journal:  Cureus       Date:  2017-11-03

8.  Malignant Progression Contributes to the Failure of Combination Therapy for Atypical Meningiomas.

Authors:  Qing Zhang; Zheng Wen; Ming Ni; Da Li; Ke Wang; Gui-Jun Jia; Zhen Wu; Li-Wei Zhang; Wang Jia; Liang Wang; Jun-Ting Zhang
Journal:  Front Oncol       Date:  2021-01-15       Impact factor: 6.244

9.  Meninigiomas of the Craniocervical Junction--A Distinctive Subgroup of Meningiomas.

Authors:  Lasse Dührsen; Pedram Emami; Jakob Matschke; Tammam Abboud; Manfred Westphal; Jan Regelsberger
Journal:  PLoS One       Date:  2016-04-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.